On January 6, 2022 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported that the Company will deliver a corporate presentation at the upcoming virtual investor conferences below (Press release, Soligenix, JAN 6, 2022, View Source [SID1234598345]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
H.C. Wainwright BioConnect Conference, held January 10 through 13, 2022 with presentations, one-on-one meetings, and networking. The on-demand presentation will be available Monday, January 10 at 7AM ET. To view the presentation, please go to View Source The presentation will be archived there for 90 days. For more information about the H.C. Wainwright BioConnect Conference, please refer to the conference website at View Source
Biotech Showcase: The Investor Conference for Innovators, held January 10 through 12, and 17 through 19, 2022 with presentations, one-on-one meetings, and networking. The presentation will be available for registered attendees beginning Monday, January 10. For more information about the Biotech Showcase Conference, please refer to the conference website at https://informaconnect.com/biotech-showcase/.
Key members of Soligenix management will hold one-on-one meetings throughout both conferences. Registered conference attendees may schedule a meeting with Soligenix via the conference scheduling platform.
If you are unable to attend the conferences and would like to schedule a meeting with management, please contact [email protected].